Skip to main content

Advertisement

SpringerLink
Log in

A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies

  • ORIGINAL COMMUNICATION
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract.

Background:

Painful HIV-associated sensory neuropathies (HIV-SN) are a common complication of HIV infection. The pathogenesis is unknown and the treatment very limited. Gabapentin (GBP) is effective in painful diabetic neuropathy and postherpetic neuralgia and its effectiveness on painful HIV-SN has been reported anecdotally.

Design:

Multicenter, prospective, randomised, double-blind, placebo-controlled study.

Methods:

Patients were followed for a 1-week screening, a 4-week double-blind and a 2-week open treatment phase. GBP was initiated at 400 mg/d, titrated over 2 weeks to 1200 mg/d, and then either maintained at this level or—if not beneficial—titrated to 2400 mg/d. After 4 weeks the medication was unblinded and the patient had the choice to begin, to maintain or to increase GBP to 3600 mg/d. The primary outcome measure was an improvement in median pain on the Visual Analogue Scale (VAS) from the screening week compared to the 4th treatment week. A secondary efficacy measure was the median sleep score (VAS).

Results:

15 patients received GBP and 11 placebo. In each group one patient dropped out during the doubleblind phase. Median pain (GBP 5.1; placebo 4.7) and sleep score (GBP 4.5; placebo 5.6) did not differ between both groups at baseline. In the GBP-group there was a significant decrease of the pain to 2.85 (–44.1 %) as well as of the sleep VAS to 2.3 (–48.9 %). No significant decrease in the pain (median VAS=3.3, –29.8 %) as well as in the sleep score (median VAS=4.95, –11.6 %) was observed in the placebo-group. GBP was generally well tolerated. The most frequent side effect was somnolence reported in 80% of GBP-treated patients.

Conclusions:

GBP was more effective than placebo in reducing pain and sleep interference in patients with HIV-SN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abdi S, Lee DH, Chung JM (1998) The anti-allodynic effects of amitryptiline, gabapentin and lidocaine in an art model of neuropathic pain. Anesth Analg 87:1360–1366

    CAS  PubMed  Google Scholar 

  2. Backonja M, Beydoun A, Edwards KR, et al. (1998) Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280:1831–1836

    CAS  PubMed  Google Scholar 

  3. Childs EA, Lyles RH, Selnes OD, et al. (1999) Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 52:607–613

    CAS  PubMed  Google Scholar 

  4. Deutsche Neuro-AIDS-Arbeitsgemeinschaft [DNAA] (2000) Erkrankungen des peripheren Nervensystems und der Muskulatur bei der HIV-Infektion. Nervenarzt 71(6):442–450

    Article  PubMed  Google Scholar 

  5. Gatti A, Jann S, Sandro B, Manuela B (1998) Gabapentin in the treatment of distal symmetric axonopathy in HIV infected patients. Neurology 50:A216 abstract (P04.053)

    Google Scholar 

  6. Griffin JW, Crawford TO, McArthur JC, et al. (1998) Peripheral neuropathies associated with HIV infection. In: Gendelman HE, Lipton SA, Epstein L, Swindells S (eds) The neurology of AIDS. New York, Chapman & Hall, pp 275–291

  7. Husstedt IW, Grotemeyer KH, Busch J, Zidek W (1994) Early detection of distal symmetrical polyneuropathy during HIV infection by paired stimulation of sural nerve. Electroencephalogr Clin Neurophysiol 93:169–174

    Article  CAS  PubMed  Google Scholar 

  8. Keswani SC, Pardo C, Cherry CL, Hoke A, McArthur JC (2002) HIV-associated sensory neuropathies. AIDS 16:2105–2117

    Article  PubMed  Google Scholar 

  9. Kieburtz K, Simpson D, Yiannoutsos C, et al. (1998) A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. Neurology 51:1682–1688

    CAS  PubMed  Google Scholar 

  10. Lange D (1994) AAEM minimonograph #41: Neuromuscular diseases associated with HIV-1 infection. Muscle Nerve 17:16–30

    CAS  PubMed  Google Scholar 

  11. La Spina I, Porazzi D, Maggiolo F, Bottura P, Suter F (2001) Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations. Eur J Neurol 8:71–75

    Article  CAS  PubMed  Google Scholar 

  12. Malessa R, Agelink M, Himmelmann M, Kloss T, Mertins L, Brockmeyer NH (1996) Nerve conduction changes in asymptomatic HIV-1 seropositive individuals in the absence of other risk factors for neuropathy. Electromyogr Clin Neurophysiol 36:3–8

    CAS  PubMed  Google Scholar 

  13. McArthur JC, Yiannoutsos C, Simpson DM, et al. (2000) A phase II trial of nerve growth factor for sensory neuropathy associated with HIV-infection. Neurology 54:1080–1088

    CAS  PubMed  Google Scholar 

  14. McQuay H, Carroll D, Moore A (1995) Variation in the placebo effect in randomised controlled trials of analgesics: all is as blind as it seems. Pain 64:331–335

    Article  Google Scholar 

  15. Newshan G (1998) HIV neuropathy treated with gabapentin. AIDS 12:219–221

    CAS  PubMed  Google Scholar 

  16. Novakovic SD, Tzoumaka E, McGivern JG, et al. (1998) Distribution of the tetrodotoxin-resistant sodium channel PN3 in rat sensory neurons in normal and neuropathic conditions. J Neurosci 18:2174–2187

    CAS  PubMed  Google Scholar 

  17. Paice JA, Estwing Ferrans C, Lashley FR, Shott S, Vizgirda V, Pitrak D (2000) Topical capsaicin in the management of HIV-associated peripheral neuropathy. J Pain Symptom Manage 19(1):45–52

    Article  CAS  PubMed  Google Scholar 

  18. Pan HL, Eisenach JC, Chen SR (1999) Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats. J Pharmacol Exp Ther 288:1026–1030t

    CAS  PubMed  Google Scholar 

  19. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L (1998) Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280:1837–1842

    CAS  PubMed  Google Scholar 

  20. Schiffito G, Yiannoutsos C, Simpson DM, et al. (2001) Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology 57:1313–1316

    PubMed  Google Scholar 

  21. Shlay JC, Chaloner K, Max MB, et al. (1998) Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy; a randomized trial. JAMA 280(18):1590–1595

    CAS  PubMed  Google Scholar 

  22. Simpson DM, Dorfman D, Olney RK, et al. (1996) Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The peptide T Neuropathy Study Group. Neurology 47:1254–1259

    CAS  PubMed  Google Scholar 

  23. Simpson DM, Olney R, McArthur JC, Khan A, Godbold J, Ebel-Frommer K (2000) A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 54:2115–2119

    CAS  PubMed  Google Scholar 

  24. Simpson DM, cArthur JC, Olney R, et al. (2003) Lamotrigine for HIV-associated painful sensory neuropathies: A placebo-controlled trial. Neurology 60:1508–1514

    CAS  PubMed  Google Scholar 

  25. Tagliati M, Grinnel J, Godbold J, Simpson DM (1999) Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Arch Neurol 56:84–89

    Article  CAS  PubMed  Google Scholar 

  26. Taylor CP,Gee NS, Su TZ, et al. (1998) A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 29:233–249

    Article  CAS  PubMed  Google Scholar 

  27. Woolf CJ, Salter MW (2000) Neuronal plasticity: increasing the gain in pain. Science 288:1765–1769

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Heinrich Heine University, Düsseldorf, Germany

    G. Arendt & H.-J von Giesen

  2. Department of Neurology, University of Münster, Germany

    I. W. Husstedt

  3. Department of Neurology, University of Duisburg-Essen, Germany

    M. Maschke

  4. Neurological Clinic, Barsinghausen, Germany

    M. E. Straube

  5. Department of Neurology, Auguste-Viktoria-Hospital, Berlin, Germany

    E. Schielke

  6. Department of Neurology, Charité Campus Mitte, Schumannstr. 20/21, D-10117, Berlin, Germany

    K. Hahn & J. S. Braun

Authors
  1. K. Hahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Arendt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. S. Braun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H.-J von Giesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. W. Husstedt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Maschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. E. Straube
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E. Schielke
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the German Neuro-AIDS Working Group

Corresponding author

Correspondence to K. Hahn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hahn, K., Arendt, G., Braun, J.S. et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 251, 1260–1266 (2004). https://doi.org/10.1007/s00415-004-0529-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-004-0529-6

Key words

Search

Navigation